NCT00032903已完成1 期
Oral ST1481 in Adults With Malignant Glioma: a Phase I-II Clinical Trial
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 59
- 试验地点
- 2
研究概览
简要总结
Gimatecan® is Sigma-Tau Research's new, potent, oral Topoisomerase I inhibitor. Drugs in this class play a crucial role in destroying DNA replication in tumors. We are conducting this study to determine the Maximum Tolerated Dose of our compound. In addition, we plan to assess the drug's ability to affect the evolution of malignant gliomas, when given as a capsule, rather than by intravenous injection.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
This is an Early Study to Investigate the Effect of Gimatecan® in Adults With Solid TumorSolid MalignanciesNCT00033202Sigma-Tau Research, Inc.30
Unknown
1 期
A Clinical Study of Gimatecan in Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer or Primary Peritoneal CancerOvarian Epithelial CancerFallopian Tube CancerPrimary Peritoneal CancerNCT04029909Lee's Pharmaceutical Limited12
招募中
1 期
Safety and Tolerability Study of GIM-531 in Advanced Solid TumorsMelanoma Stage IVSolid TumorNCT06425926Georgiamune Inc117
进行中（未招募）
不适用
A Phase II study of oral gimatecan ST 1481 in progressing or recurring patients with advanced epithelial ovarian, fallopian or peritoneal cancer, previously treated with platinum and taxanesAdvanced epithelial ovarian, fallopian or peritoneal cancerMedDRA version: 6.1Level: PTClassification code 10018160EUCTR2005-000595-40-ITSIGMA-TA56
终止
1 期
This Is The First Study Using Escalating Doses Of PF-03758309, An Oral Compound, In Patients With Advanced Solid TumorsAdvanced Solid TumorsNCT00932126Pfizer35